Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gilead Sciences
BioNTech SE
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Wake Forest University Health Sciences
ToLymph Inc.
Neonc Technologies, Inc.
Pfizer
AstraZeneca
Bristol-Myers Squibb
AstraZeneca
AstraZeneca
Amgen
Hackensack Meridian Health
Merck Sharp & Dohme LLC
Intergroupe Francophone de Cancerologie Thoracique
Eli Lilly and Company
Second Affiliated Hospital of Nanchang University
University of Utah
Abramson Cancer Center at Penn Medicine
Intergroupe Francophone de Cancerologie Thoracique
Fate Therapeutics
Shanghai Hengrui Pharmaceutical Co., Ltd.
Fundación GECP
BioNTech SE
Weill Medical College of Cornell University
Nurix Therapeutics, Inc.
University of Alabama at Birmingham
First Affiliated Hospital of Zhejiang University
Shanghai Junshi Bioscience Co., Ltd.
Hospital Sultanah Bahiyah
Iovance Biotherapeutics, Inc.
Peking University Cancer Hospital & Institute
Shanghai Junshi Bioscience Co., Ltd.
Stanford University
Fox Chase Cancer Center
Qilu Pharmaceutical Co., Ltd.
Hunan Province Tumor Hospital
Mabscale, LLC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
State University of New York - Upstate Medical University